drugset / Trial / NCT01877837

Stem Cell Transplantation for Sickle Cell Anemia

NCT01877837

Phase 3 Completed 30 enrolled Hackensack Meridian Health
NaSingle-groupOpen-labelTreatment

Summary

This protocol will be investigating the use of stem cell transplantation, in related donors, to cure sickle cell disease. Sickle cell disease is a recessive disorder caused by a point mutation that results in the substitution of valine for glutamic acid at the sixth position in the B-chain of hemoglobin. This leads to sickling of the red blood cells under many conditions, such as hypoxia, dehydration, and hyperthermia. The sickling leads to vaso-occlusion, which causes irreversible damage in almost all systems in the body, including the central nervous system (CNS), lungs, heart, bones, eyes, liver, and kidneys.

Timeline

Start
2011-06
Primary completion
2021-09
Completion
2021-09

Drugs

EvaluationDrugModalityDoseRoute
Background Alemtuzumab Monoclonal antibody 20 mg Intravenous
Background Fludarabine Small molecule 30 mg/m2 Intravenous
Background Melphalan Small molecule 140 mg/m2 Intravenous

Indications